Obesity - Lack of Reimbursement Limits Market Potential

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-12-20

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor predicts a somewhat enthusiastic uptake of two agents currently in development by 2015. However, reimbursement is critical to the uptake of new medication, due to the high cost of therapy. If the reimbursable status is not achieved, the expansion of the market will not match the rate of growth of the obese population and the great potential of the obesity market will remain untapped.


Scope

  • Assessment of the patient potential for developmental anti-obesity agents over the period 2006-15
  • Overview of the anti-obesity R&D pipeline, with detailed information on the classes in development and comparator drugs
  • Commercial analysis of key compounds in development regarding their ability to take away market share from the currently available drugs
  • Sales forecasts for key late-stage developmental anti-obesity agents in the seven major markets to 2015


    • Report Highlights
    The obesity epidemic is taking place to a certain extent in all the major markets, and the rate of obesity prevalence growth is not showing any signs of slowing down in the near future.

    The anti-obesity market growth does not follow the growth of obesity prevalence. The major cause for the lack of growth in most of the major markets is lack of reimbursement for pharmacological management of obesity.

    The drugs currently available in the major markets for treatment of obesity have significant unmet needs and do not meet the expectations of obese patients. The pipeline drugs will be able to expand the market. However, the growth of the market will still be marginal in comparison to the growth of obesity prevalence.


    Reasons to Purchase

  • Understand the key factors that will contribute to the success of the next generation of anti-obesity drugs
  • View independent sales forecasts for products in late stage development for therapy of obesity
  • Understand physician sentiment on clinical trial endpoints and late-stage candidate drugs for the obesity market

    • Table of Contents

    Other users found this report page using the following search terms: obesity reimbursement insurance obesity reimbursement market xenical japan drug orlistat swot acomplia analysis

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.